SBH Sciences. Innovative Biotechnology Company with Two Discovery Programs. Discovery and Pre-clinical Contract Research Organization (CRO)

Transcription

1 SBH Sciences Innovative Biotechnology Company with Two Discovery Programs Discovery and Pre-clinical Contract Research Organization (CRO) Production and Bioassay Testing of Cytokines & Enzymes Bio-Incubator : An Innovative Business Model Models for Oncology and Inflammation Custom Process Development Biomarkers Analysis September 2017

2 Therapeutic Areas Supported by SBH In-Vitro Models Oncology (350 human cancer cell lines) Inflammation (human PBMC, THP-1, Liver and BEAS-2B cells) Metabolic diseases (Diabetes, NASH) Neurobiology (Neurodegeneration / Neuroprotection) Clone Selection Cell Culture Optimization Purification BioProcess Scale-up Formulation Manufacturing Target ID Assay Development Primry Screening Secondary Screening Lead Optimization PK/PD Serving More Than 180 companies worldwide for 20 years

3 Capabilities Biological Resources 350 human tumor cell lines > 30 oncology drugs > 300 cytokine potency assays 30 Recombinant cytokines 8 Recombinant enzymes 40 Monoclonal antibodies PBMC, THP-1 inflammation assays Other potency assays Instrumentation 2D Western Blot Luminex 200 Simple Plex (Ella) Fully Automatic ELISA Workstation Analytical HPLC qrt-pcr Vitros 350 analyzer Irradiation Capability FACS Screening Services Biomarker Analysis Multiplex Kit Development 3

4 Extended Capabilities Biologics Support Bench-scale production Pilot scale-up Purification Basic CMC, stability Formulation In-Silico Biologics Development Services Facilities Cell culture lab Protein purification lab Biomarker lab Bio-Incubator ABI-LAB Currently support 14 companies Partners In-vivo services (oncology & NASH) CLIA / CAP Certification Consulting 4

5 5 Production of Biologics

6 Cell Culture Services (Mammalian & Insect Cells) Production of recombinant proteins, monoclonal antibodies, and vaccines Optimization of growth conditions (media optimization and serum-free adaptation) Supply any mammalian cell lines before and after cytokines stimulation Customized services (10 human primary cells and > 400 mammalian cell lines are currently available) 2D and 3D capabilities Irradiation experiments (combination therapy) Protein Purification Services Development of scalable, well understood, and reproducible purification processes LC capability (Ion Exchange, HIC, Affinity, Metal, HA, SEC) HPLC (Preparative and Analytical methods development) Protein formulation and stability studies

7 SBH Sciences has Produced and Commercialized 78 Cytokines and other Biologics 38 Recombinant proteins and 40 monoclonal antibodies TGF-Beta (TGF-b2) Interleukins (IL-12, IL-23) Growth Factors (HGF) Activin-A GDF-15/MIC-1 Bone Morphogenic Proteins (BMP-2, BMP-7) Soluble receptors (s-il-6r) IGF-BPs (IGF-BP-6) Interferon (IFN-b) Enzymes (8 Glycosyltransferase) CD22 TNF Receptor (HVEM-Fc) Anti-Galectin Anti-TNFa Anti-VEGF All products are > 95% pure, tag-free, and carrier-protein free

8 Cell-Based Assay Capabilities Inflammation, oncology, and fibrosis are the therapeutic areas where SBH Sciences is best positioned to assist you. 300 cell-based assays to measure cytokine activity (cytokine-induced proliferation, cytokine-induced killing, cytokine release assays, and cytokine neutralization). Screening of therapeutic antibodies for specific activity (includes receptor binding assays, ADCC and ADCP assays). 350 different human cancer cell lines to facilitate in-vitro lead drug optimization (cytotoxicity, invasion, and migration assays). Cell-based disease models for compound selection (inflammation / fibrosis THP-1, BEAS-2B, and immortalized liver cell line).

9 R&D Systems : Measured by its ability to induce hemoglobin expression in K562 human chronic myelogenous leukemia cells. Schwall, R.H. et al. (1991) Method Enzymol. 198:340. The ED50 for this effect is typically 2-10 ng/ml.

10 R&D Systems : Measured in a cell proliferation assay using BaF3 mouse pro-b cells transfected with mouse Flt-3. No ED50.

11 Existing Platforms to Assist with Biomarker Analysis AlphaScreen and AlphaLISA Simple Plex: ProteinSimple ELLA ELISA [Freedom EVO; TECAN] Flow Cytometry HTRF / TR-FRET Luminex 200 [Multiplex] Automated Western Blot [PeggySue / Wes] Analytical HPLC RT-PCR Chemical analyzer, VITROS

12 Comprehensive Biomarker Analysis Services We offer 10 platforms that already being used for the analysis of thousands clinical samples (> 100 biomarkers). First CRO to offer automated simple western blot services on PeggySue and WES. First CRO to offer Simple Plex assays on ELLA. SBH Diagnostics, our strategic partner, is a contract research organization providing: CLIA certification CAP accreditation Translation from non-regulated to regulated environment 12

13 OD (405nm nm) Development of Receptor Binding Assay for VEGF-165 Coating : VEGF-R1 Detection: Polyclonal anti-vegf Lot release based on active VEGF VEGF-165 (ng/ml) [log scale] Final Pool "UK" Day 39 (2/16/10) Day 41 (2/16/10) Day 42 (2/16/10)

14 14 Multiplex multi-array analysis (Luminex 200)

15 2D Western for Biomarker Discovery Utilizing Protein Simple s PeggySue and WES - automated Western Blotting systems, SBH can rapidly analyze multiple samples for a specific biomarker PeggySue: For characterization of expressed proteins in a biologic sample.

16 Comprehensive Pathway Analysis (Companion Biomarkers) MAP Kinases JAK/STAT Apoptosis Pathways Stress Response NFkB Cell Cycle

17 Drug A Drug B A549 p44/42 MAPK (Erk1/2)

18 Drug Response in FNAs a-phospho-stat 5 Day 0 No Treatment Day 3 Gleevec

19 Oncology a strategic collaboration 19

20 MM.1S BL-41 BL-40 Jurkat A-375 MM.1R LnCap HCT-116 RWPE-1 HS-Sultan BL-2 PC3 AML-5 MG-63 Colo-201 SW-480 U2OS SJSA Colo-205 NCI-H460 NCI-H226 LoVo Colo-205 SW-403 Colo-320HSR HTB-119 RPMI8226 NCI-H28 SW-620 PANC-1 LS-123 Colo-320DM SW-1417 MCF-7 C2BBe1 HEL HCT-15 SW O U266 SW-948 Paca-2 HCT-15 Raji 4T1 PL-45 Hela HPAC Hut-78 Caov-3, HTB-75 DLD-1 T47D DU-145 SW-626 LS-180 KG-1 HCT-8 HTB-38 WiDr Hep-G2 Cytotoxicity (IC50 [mm]) Cancer Cell Cytotoxicity (72 hours) human cancer cells are ready for immediate studies

21 Integrated in vivo and in vitro Services Streamlined data transfer into animal models Efficacy studies ; PK/PD modeling Standard to advanced modeling, including primary patient tumors Shorter development time and enhanced project success!

22 Untreated GBM GBM spheroid 3D culture system with U87MG Glioblastoma cell line The radial spread in two dimensions is reminiscent of the natural disease. Not shown here is the invasion down into the substrate as well Spheroid outgrowth over 8 days (boxes = 250 um) 1 represents initial spheroid plated

23 Irradiation Capability U87MG cell line

24 Integrated in-vivo and in-vitro Services Inflammation and Liver Fibrosis

25 OD ( nm) Development of In-Vitro Inflammation Model using Human PBMC Evaluation of potential Drug in the presence of LPS OD from ELISA measurement of h-tnfa Drug (um) [log scale] 100% Neutralization Drug 25

26

27 January 27, 2014 Galectin Therapeutics and SBH Sciences, Announce the Formation of Galectin Sciences, LLC, a Collaborative Venture to Research and Develop Galectin Inhibitors for Oral Administration 27

28 Clinical Product Development - Case Study: human IL-12 a Novel Radiation Medical Countermeasure Proprietary human IL-12 production process was developed by SBH Sciences COA established for commercial release to the R&D market Neumedicines, Inc. (CA) licensed the technology from SBH Sciences In 2008, both companies collaborated to secure a Biomedical Advanced Research and Development Authority (BARDA) contract to develop IL-12 for Acute Radiation Syndrome In 2009, SBH Sciences optimized the process, scale-up, and transferred the technology to a GMP manufacturing April 2011 Submission of IND June 2011 First-In-Human for Toxicity studies 28

29 Significant Impact SBH Sciences is innovative biotechnology company and pre-clinical contract research organization which has been in operation for 20 years, providing over 180 companies with quality products and services. SBH Sciences supported and guided 3 companies through all stages of drug development, bringing 7 NCE s to clinical trials. 29

30 President & CSO Regulation QA / QC Operations & Safety Manager Office Manager and Treasurer Director of Business Development Website & IT

31 President & CSO Cell Culture Protein Purification Biomarker Bioassay Discovery Supervisor Supervisor Supervisor Supervisor Senior Scientist Associate Scientist Scientist Lab Coordinator Scientist Consultant Molecular Modeling Associate Scientist Associate Scientist Associate Scientist Associate Scientist Associate Scientist

32 Raphael Nir, Ph.D. President and CSO Tel: v